Background:

The HCV Drug Resistance Advisory Group (HCV DRAG) is an outgrowth of a proposal from the 1st International Workshop on Hepatitis C: Resistance and New Compounds in October 2006.

Objectives:

The objective of the HCV DRAG is to bring together parties interested in and working in HCV drug resistance to continue discussions focused on issues pertinent to HCV drug/biologic development and resistance testing.  

The goals are to produce consensus recommendations of appropriate methodology for HCV resistance testing for drug/biologic development and for clinical practice; and to provide scientific guidance to facilitate discussion between industry and regulatory agencies in areas of HCV drug resistance.

Status:

The second HCV DRAG meeting was on November 2nd, 2007.

The Planning Committee for this project includes:

Charles Boucher - Utrecht University
Nick Cammack - Roche
Ben Cheng - Forum for Collaborative HIV Research
Dale Kempf - Abbott
Ann Kwong - Vertex
Veronica Miller - Forum for Collaborative HIV Research
Jules O'Rear - FDA
Neil Parkin - Monogram Bioscience
Chip Schooley - UC San Diego